Semaphore launches human testing of cancer drug

March 26, 2007

Phase 1 clinical trials have been started at Indiana University and a site in Arizona of Semaphore Pharmaceuticals Inc.’s cancer tumor drug.

The Indianapolis company has seen success in animal trials in an array of tumors. Semaphore’s P13K inhibitor targets the “master switch” that signals cancer cells to grow.

Source: XMLFULL/XMLFull1004.xml

Recent Articles by IBJ Staff

Comments powered by Disqus